References

1. Annie Wong, Beringer 2001. Therapeutic challenges associated with extended spectrum, beta lactamase producing Esche-richia coli and Klebsiella pneumonia.  Pharmacotheraphy Publications, p.583-592.
2. Sturenburg E, Mac D, 2003, Extended spectrum, beta lactamases. Implications for the clinical microbiology laboratory, therapy and infection control J. Infection. 273-95.
3. Patricia A, Bradford (2001). Extended-Spectrum β – lactamases in the 21^st  Characterization, Epidemology and detection of this important resistance threat.  Clinical Microbiology review, p.933-951.
4. Daoud N, Hakime et al (2003). Prevalence and susceptibility patterns of extended-spectrum β – lactamases producing Escherichiae coli and Klebsiella pnumoniae in general university hospital in Beirut, Lebanon, Rev.Esp.Quimioterap, Junio 233-238.
5. Philip E. Coudron, 1997. Occurrence and detection of Extended Spectrum-β – lactamases in member of the Family Enterobacteriaceac at a Veterans Medical Center : Seek and You May Find. Journal of Clinical Microbiology, p.2593-2597.
6. Prabha Unnikrishnan. Extended- Spectrum- β – lactamases :
7. Evolution, Detection, Clinical Significance and opportunities for control. The Journal of the Academy of Clinical Microbiologist, 2002;4(2):67-73,
8. Surakit Nathisuwan, David S. Burgess, James S et al. Extended- Spectrum- β – lactamases : Epidemiology, Detection and Treatment. Pharmacotherapy 2001; 21(8): 920-928.
9. John Heritage, Fathima H, M’Zali et al (1999), Evolution and spread of SHV extended Spectrum- β – lactamases in gram-negative bacteria. Journal of Antimicrobial Chemotheraphy, p.309-318.
10. Christine Kliebe, Berthold A, Nies et al. 1985. Evolution of plasmid-coded resista-nce to broad-spectrum cephalosporins.  Antimicrobial Agents and Chemotherapy, p.302-307.
11. Adolf Bauernfeind, Yunsop Chong et al (1998). Plasmid-Encoded Amp.C β – lactamases: How far have we gone 10 years after the discovery?  Yonsei Medical Journal, Vol.39; No.6, pp.520
12. Carmen Pena, Miquel Pujol, Carmen Ardanuy et al, Asumpta Ricart et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumonia producing extended spectrum β -lactamases.  Antimicrobial Agents and Chemotherapy, 1998, Vol.42 (1):53-58.
13. Thomson KS, Prevan AM & Sanders CC. β-lactamases in enterobacteriaceae : Emerging problem for new β-lactam antibiotics. Curr Clin Top Infect Dis. 1996; 16: 151-163.
14. Harjeet Kaur, Gurvinder, Efficacy of β-lactam – Inhibitor Drug Combinations against Extended Spectrum β-lactamase positive gram negative organisms.2003;3 (4):183-85.
15. Phlippon A. Labia R & Jacoby G. Exten-ded- spectrum β-lactamases. Antimicrob Agents Chemother. 1989; 33: 1131-1136.
16. Ananthakrishna AN, Kanugo R, Kumar A et al. Detection of a extended spectrum β-lactamases producers among surgical wound infections and burns patients in JIPMER.  Indian J Med Microbiol 2000, 18: 160-165.
17. Gold HS & Moellering RC Jr. Antimicrobial Drug Resistance.N Eng J Med 1996;335 (19): 1445-1452.
18. Tenover FC, Raney PM, Williams PP, Rasheed JK, Williams PP, Rasheed JK, Biddle JW, Oliver A, Fridkin SK, Jevitt L, McGowan JE Jr. Evaluation of the NCCLS extended - spectrum β-lactamase confir-mation method for Escherichia coli with isolates collected during project ICARE. J Clin Microbiol 2003; 41(7):3142-6.
19. Casellas JM, Goldberg M. Incidence of strains producing extended - spectrum β-lactamases in Argentina. Infection 17:434-436
20. Patricia A.Bradford, Carl Urban, Noriel Mariano, Steven J.Projan, James J.Rahal and Karen Bush.  Imipenem resistance in Klebsiella pneumonia is associated with the combination of ACT-1, a Plasmid-Mediated AmpC- β – lactamase, and the loss of an outer membrane protein.  Antimicrobial Agents and Chemotherapy, 1997, 41(3):563-569.

Corresponding Author

Dr Mini Palathingal Narayanan

Associate Professor in Microbiology,

Govt Medical College, Kozhikode